{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:48:41Z","timestamp":1782762521166,"version":"3.54.5"},"reference-count":21,"publisher":"Informa UK Limited","issue":"30","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Immutep S.A.S"},{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"},{"name":"Immutep S.A.S"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,12,20]]},"DOI":"10.1080\/14796694.2025.2597404","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:43:43Z","timestamp":1765529023000},"page":"3885-3890","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer"],"prefix":"10.1080","volume":"21","author":[{"given":"Kenneth","family":"O\u2019Byrne","sequence":"first","affiliation":[{"name":"Greenslopes Private Hospital, Greenslopes, Australia and Queensland University of Technology (QUT)","place":["Brisbane, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Esteban","sequence":"additional","affiliation":[{"name":"Hospital Universitario Central de Asturias","place":["Oviedo, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheen Leng","family":"Lee","sequence":"additional","affiliation":[{"name":"Penang General Hospital","place":["George Town, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alinta","family":"Hegmane","sequence":"additional","affiliation":[{"name":"Riga East University Hospital","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Volovat","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, Romania and Center of Oncology Euroclinic","place":["Iasi, Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lo Russo","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale dei Tumori","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ziogas","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akin","family":"Atmaca","sequence":"additional","affiliation":[{"name":"UCT-University Cancer Center Frankfurt-Marburg","place":["Frankfurt\/Main, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sebastian","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt, Frankfurt, Germany and Frankfurt Cancer Institute","place":["Frankfurt, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20332"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02885"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005921"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00226-1"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-71"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0068"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.6.4202"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/OA-24-00102"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100725"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0473"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605465"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.728018"},{"key":"e_1_3_7_18_1","volume-title":"Teluride-005: phase II study of EIK1001, a toll-like receptor 7\/8 (TLR7\/8) co-agonist with pembrolizumab (pembro)+chemotherapy (chemo) as first-line (1L) therapy in stage 4 non-small cell lung cancer (NSCLC) [mini oral presentation]","author":"Gralla RJ","year":"2025","unstructured":"Gralla RJ, editor. Teluride-005: phase II study of EIK1001, a toll-like receptor 7\/8 (TLR7\/8) co-agonist with pembrolizumab (pembro)+chemotherapy (chemo) as first-line (1L) therapy in stage 4 non-small cell lung cancer (NSCLC) [mini oral presentation]. Berlin: ESMO; 2025."},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2481"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.06.012"},{"issue":"754","key":"e_1_3_7_21_1","article-title":"Combining the antigen-presenting cell activator eftilagimod alpha (soluble lag-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)","volume":"34","author":"Iams W","year":"2022","unstructured":"Iams W,Felip E Majem M, et al. Combining the antigen-presenting cell activator eftilagimod alpha (soluble lag-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II). Ann Oncol. 2022;34(S754).","journal-title":"Ann Oncol"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01990"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2597404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2025.2597404","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2597404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:19:27Z","timestamp":1782760767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2597404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":21,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2025,12,20]]}},"alternative-id":["10.1080\/14796694.2025.2597404"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2597404","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}